WO2005080556A3 - Virus purification methods - Google Patents

Virus purification methods Download PDF

Info

Publication number
WO2005080556A3
WO2005080556A3 PCT/EP2005/050739 EP2005050739W WO2005080556A3 WO 2005080556 A3 WO2005080556 A3 WO 2005080556A3 EP 2005050739 W EP2005050739 W EP 2005050739W WO 2005080556 A3 WO2005080556 A3 WO 2005080556A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
host cells
recombinant
recombinant virus
lysing
Prior art date
Application number
PCT/EP2005/050739
Other languages
French (fr)
Other versions
WO2005080556A2 (en
WO2005080556A9 (en
Inventor
Miranda Weggeman
Corven Emile Joannes Josep Van
Original Assignee
Crucell Holland Bv
Miranda Weggeman
Corven Emile Joannes Josep Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34878416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005080556(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/590,427 priority Critical patent/US20070207461A1/en
Priority to EP05729676A priority patent/EP1718738A2/en
Priority to DK06126383T priority patent/DK1780269T3/en
Priority to CA2555412A priority patent/CA2555412C/en
Priority to NZ548495A priority patent/NZ548495A/en
Application filed by Crucell Holland Bv, Miranda Weggeman, Corven Emile Joannes Josep Van filed Critical Crucell Holland Bv
Priority to JP2006553596A priority patent/JP2007522814A/en
Priority to AU2005214090A priority patent/AU2005214090B2/en
Publication of WO2005080556A2 publication Critical patent/WO2005080556A2/en
Publication of WO2005080556A3 publication Critical patent/WO2005080556A3/en
Priority to KR1020067017560A priority patent/KR101211329B1/en
Publication of WO2005080556A9 publication Critical patent/WO2005080556A9/en
Priority to US12/220,828 priority patent/US8124106B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides a method for the purification of a virus from a host cell, said method comprising the steps of: a) culturing host cells, b) infecting said host cells with a virus, c) treating the cell culture with nuclease, d) lysing said host cells to provide a lysate comprising the virus. The virus is preferably a recombinant adenovirus. The invention further provides a method for the purification of a recombinant virus expressing a heterologous protein that is capable of binding nucleic acid, comprising the steps of: a) culturing host cells, b) infecting said host cells with said recombinant virus, c) lysing said host cells to provide a lysate comprising said recombinant virus, d) subjecting the recombinant virus to anion exchange chromatography and size exclusion chromatography, characterized in that the virus containing mixture is buffer exchanged at least once with a solution comprising at least 2 M NaCl, or another salt providing an equivalent ionic strength.
PCT/EP2005/050739 2004-02-23 2005-02-21 Virus purification methods WO2005080556A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2005214090A AU2005214090B2 (en) 2004-02-23 2005-02-21 Virus purification methods
EP05729676A EP1718738A2 (en) 2004-02-23 2005-02-21 Virus purification methods
DK06126383T DK1780269T3 (en) 2004-02-23 2005-02-21 Virus Purification Methods
CA2555412A CA2555412C (en) 2004-02-23 2005-02-21 Virus purification methods
NZ548495A NZ548495A (en) 2004-02-23 2005-02-21 Virus purification methods
US10/590,427 US20070207461A1 (en) 2004-02-23 2005-02-21 Virus Purification Methods
JP2006553596A JP2007522814A (en) 2004-02-23 2005-02-21 Virus purification method
KR1020067017560A KR101211329B1 (en) 2004-02-23 2006-08-30 Virus purification methods
US12/220,828 US8124106B2 (en) 2004-02-23 2008-07-28 Virus purification methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP04/050190 2004-02-23
EP2004050190 2004-02-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/590,427 A-371-Of-International US20070207461A1 (en) 2004-02-23 2005-02-21 Virus Purification Methods
US12/220,828 Division US8124106B2 (en) 2004-02-23 2008-07-28 Virus purification methods

Publications (3)

Publication Number Publication Date
WO2005080556A2 WO2005080556A2 (en) 2005-09-01
WO2005080556A3 true WO2005080556A3 (en) 2006-02-23
WO2005080556A9 WO2005080556A9 (en) 2006-10-26

Family

ID=34878416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/050739 WO2005080556A2 (en) 2004-02-23 2005-02-21 Virus purification methods

Country Status (13)

Country Link
US (2) US20070207461A1 (en)
EP (2) EP1718738A2 (en)
JP (1) JP2007522814A (en)
KR (1) KR101211329B1 (en)
CN (2) CN1922308A (en)
AT (1) ATE435906T1 (en)
AU (1) AU2005214090B2 (en)
CA (1) CA2555412C (en)
DE (1) DE602005015332D1 (en)
DK (1) DK1780269T3 (en)
ES (1) ES2329607T3 (en)
NZ (1) NZ548495A (en)
WO (1) WO2005080556A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633565T3 (en) 1995-06-15 2013-01-17 Crucell Holland B.V. PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRES, FOR USE IN GENE THERAPY
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
ES2329607T3 (en) 2004-02-23 2009-11-27 Crucell Holland B.V. VIRUS PURIFICATION METHODS
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
ES2359214T5 (en) 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Viral vaccines derived from cells with reduced levels of residual cellular DNA by treatment with beta-propiolactone
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
SI2007883T1 (en) * 2006-04-20 2012-02-29 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
ES2401162T3 (en) 2007-10-02 2013-04-17 Ptc Phage Technology Center Gmbh Procedure and system for industrial scale purification of bacteriophages intended for bacteriophage therapy
AU2009214768B2 (en) * 2008-02-12 2015-01-22 Sanofi Pasteur Limited Methods using ion exchange and gel filtration chromatography for poxvirus purification
ES2762864T3 (en) * 2008-06-18 2020-05-26 Oxford Biomedica Ltd Virus purification
KR20110074563A (en) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 Methods for purification of viruses
WO2010060719A1 (en) * 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
US20110293660A1 (en) * 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
JP2010207800A (en) * 2009-02-16 2010-09-24 Kuraray Co Ltd Filtration unit, and filtration apparatus including the same
JP2010193720A (en) * 2009-02-23 2010-09-09 Asahi Kasei Chemicals Corp Method for separating virus using porous membrane having immobilized anion exchange group
CA2761457A1 (en) * 2009-05-12 2010-11-18 Transgene Sa Immortalized avian cell lines and use thereof
US20120141980A1 (en) * 2009-08-17 2012-06-07 Merk Patent Gesellschaft Mit Beschrankter Haftung Method for isolating viruses
JP5393896B2 (en) * 2009-10-15 2014-01-22 クルセル ホランド ベー ヴェー Method for purifying adenovirus particles
US8470585B2 (en) 2009-10-15 2013-06-25 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
PL2536829T3 (en) * 2010-02-15 2016-09-30 Method for the production of Ad26 adenoviral vectors
BR112012026095A2 (en) 2010-04-14 2015-09-15 Emd Millipore Corp methods of producing high purity virus stocks and high titers and methods of using them.
WO2012010280A1 (en) * 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
CN103052399B (en) * 2010-08-12 2016-06-29 依生生物制药控股有限公司 For reducing the method for DNA impurity in virus composition
CN103118702A (en) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 Therapeutic vaccination against active tuberculosis
MX354752B (en) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Heterologous prime boost vaccination regimen against malaria.
DE102010046817A1 (en) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh A method for separating viruses from a contaminant-containing liquid medium
CN103717731B (en) * 2010-11-26 2016-06-29 普罗拜奥根股份公司 Host cell constituents is removed in live-virus vaccine
US20140193876A1 (en) * 2011-06-13 2014-07-10 Aaron R. Goerke Methods of purification of native or mutant forms of diphtheria toxin
CN110684745A (en) * 2011-07-27 2020-01-14 韦克塔里斯公司 Virus-based vector compositions useful for transduction of eukaryotic cells
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2013135615A1 (en) 2012-03-12 2013-09-19 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
MY169331A (en) 2012-03-22 2019-03-21 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
CN103571800B (en) * 2012-07-27 2018-04-24 江苏康润生物科技有限公司 A kind of method of host DNA in removal vaccine
RU2493872C1 (en) * 2012-08-08 2013-09-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации ( ФГУП "НПО "Микроген" Минздрава России) Method for influenza virus purification
CN103768589B (en) * 2012-10-18 2016-12-21 辽宁成大生物股份有限公司 Hollow-fibre membrane is utilized to remove the method for residual DNA in encephalitis B used for human being vaccine product
WO2014131898A1 (en) * 2013-02-28 2014-09-04 Psioxus Therapuetics Limited A process for the production of adenovirus
KR102236497B1 (en) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble prefusion rsv f polypeptides
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US10294460B2 (en) * 2014-07-24 2019-05-21 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
RS58080B1 (en) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
EP3307878B1 (en) * 2015-06-10 2021-08-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Processes for production and purification of nucleic acid-containing compositions
PL3319633T3 (en) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv
EP3319634B1 (en) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
AU2016309743B2 (en) 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
SI3439672T1 (en) 2016-04-05 2021-02-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
JP7233928B2 (en) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Vaccine against RSV
WO2017192418A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
CN109154000B (en) 2016-05-12 2022-07-05 扬森疫苗与预防公司 Efficient and balanced bidirectional promoters
EA039124B1 (en) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Stabilized pre-fusion rsv f proteins
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
CN106434571A (en) * 2016-10-19 2017-02-22 深圳源兴基因技术有限公司 Method for preparing recombinant adenovirus by WAVE serum-free culture suspension cells
US10294452B2 (en) 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
CN108085301B (en) * 2016-11-22 2021-10-26 贺道耀 Method for extracting and purifying adeno-associated virus and adenovirus from host cell, and components and kit thereof
BR112019015671A2 (en) 2017-02-09 2020-04-14 Janssen Vaccines & Prevention Bv potent and short promoter for expression of heterological genes
CN106868025B (en) * 2017-03-13 2020-01-21 中国人民解放军军事医学科学院生物工程研究所 Method for preparing tripolymer Ebola virus glycoprotein mutant by using yeast
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CN107603959A (en) * 2017-08-30 2018-01-19 四川大学 The method for improving buffer solution salt ionic concentration purified virus
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
US11603527B2 (en) * 2017-12-27 2023-03-14 Global Life Sciences Solutions Usa Llc Method and kit for viral vector isolation
GB201814590D0 (en) * 2018-09-07 2018-10-24 Oxford Biomedica Ltd Viral vector production system
CN110317832B (en) * 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 GMP (good manufacturing practice) scale preparation method of purified preparation of recombinant lentiviral vector
US20210047626A1 (en) 2018-04-24 2021-02-18 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US10822591B2 (en) 2018-06-12 2020-11-03 Kentucky Bioprocessing, Inc. Virus purification
WO2020229906A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Efficient impurity removal using a diafiltration process
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
WO2020264411A1 (en) * 2019-06-28 2020-12-30 Baxalta Incorporated Adeno-associated virus purification methods
CN111249456A (en) * 2020-03-13 2020-06-09 武汉生物制品研究所有限责任公司 Purification method of rabies virus inactivated vaccine
CN111394390A (en) * 2020-03-26 2020-07-10 赛诺（深圳）生物医药研究有限公司 Method for batch production of recombinant adenovirus for novel coronavirus gene vaccine
EP4259777A1 (en) 2020-12-10 2023-10-18 Sarepta Therapeutics, Inc. Suspension mode seed train development for adherent cells
AU2022279062A1 (en) 2021-05-17 2024-01-04 Sarepta Therapeutics, Inc. Production of recombinant aav vectors for treating muscular dystrophy
CA3228669A1 (en) * 2021-08-10 2023-02-16 Ganesh Ramachandran Purification of liraglutide
CN113817689B (en) * 2021-11-22 2023-10-03 北京艺妙神州医药科技有限公司 Lentivirus purification process
WO2023187691A1 (en) * 2022-03-30 2023-10-05 Csl Behring Llc Methods of purifying an enveloped virus
CN115141813A (en) * 2022-07-29 2022-10-04 深圳源兴基因技术有限公司 Adenovirus purification method for efficiently removing residual proteins of host cells
WO2024064913A1 (en) 2022-09-23 2024-03-28 Sarepta Therapeutics, Inc. Recombinant aav vectors for treating muscular dystrophy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US20020182723A1 (en) * 1998-12-01 2002-12-05 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
WO2003097797A2 (en) * 2002-05-14 2003-11-27 Merck & Co., Inc. Methods of adenovirus purification

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434914B (en) * 1975-07-07 1984-08-27 Jonsson U R S PROCEDURE TO CANCEL A SUSPENSION OF BACTERIES AND A LIQUID MEDIUM BY FILTERING Separate the media while simultaneously enriching the bacteria
US4435289A (en) * 1981-12-23 1984-03-06 Romicon, Inc. Series ultrafiltration with pressurized permeate
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US4808315A (en) * 1986-04-28 1989-02-28 Asahi Kasei Kogyo Kabushiki Kaisha Porous hollow fiber membrane and a method for the removal of a virus by using the same
FR2705686B1 (en) * 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
FR2716682B1 (en) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Process for the preparation of recombinant adeno-associated viruses (AAV) and uses thereof.
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (en) * 1994-06-10 2006-09-15 Genvec Inc ADENOVIRUS VECTOR SYSTEMS AND CELL LINES
SE9500724D0 (en) 1994-06-23 1995-02-24 Pharmacia Ab Filtration
US5965541A (en) * 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DE69633565T3 (en) * 1995-06-15 2013-01-17 Crucell Holland B.V. PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRES, FOR USE IN GENE THERAPY
FR2737730B1 (en) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc PROCESS FOR PURIFYING VIRUSES BY CHROMATOGRAPHY
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
CA2625279A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) * 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
AU3447097A (en) * 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
FR2751343B1 (en) * 1996-07-16 1998-12-18 Transgene Sa PROCESS FOR THE PRESERVATION OF INFECTIOUS RECOMBINANT VIRUSES, AQUEOUS VIRAL SUSPENSION, AND USE AS A MEDICAMENT
IL131014A0 (en) 1997-01-31 2001-01-28 Schering Plough Corp Methods for cultivating cells and propagating viruses
US6168944B1 (en) * 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
JP2000509614A (en) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド Adenovirus E1-complementation cell line
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5947689A (en) * 1997-05-07 1999-09-07 Scilog, Inc. Automated, quantitative, system for filtration of liquids having a pump controller
ES2281929T3 (en) * 1997-08-28 2007-10-01 Cheil Jedang Corporation VIRUSES OF ATTENATED JAPANESE ENCEPHALITIS ADAPTED TO VERO AND VACCINE CELLS AGAINST JAPANESE ENCEPHALITIS.
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
CN100374551C (en) 1998-02-17 2008-03-12 先灵公司 Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
SK15682000A3 (en) * 1998-04-22 2001-05-10 Genvec, Inc. Efficient purification of adenovirus
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6342384B1 (en) * 1998-08-21 2002-01-29 The University Of Va Patent Foundation Production of adenoviral vectors using serum-free suspension cell culture in a hollow fiber system
DE69940354D1 (en) 1998-11-16 2009-03-12 Introgen Therapeutics Inc ADENOVIRUS FORMULATIONS FOR GENE THERAPY
JP2003523169A (en) * 1998-12-31 2003-08-05 アバンテイス・フアルマ・エス・アー Virus particle isolation method
US6120820A (en) * 1999-02-22 2000-09-19 Land O'lakes, Inc. Method of modifying the color of a dairy material
CA2364934C (en) 1999-02-22 2011-10-18 Transgene S.A. Method for obtaining a purified viral preparation
DE60014489T3 (en) 1999-05-17 2010-08-12 Crucell Holland B.V. Adenovirus-derived gene transfer vehicles containing at least one type adenovirus type 35 element
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
DE19955558C2 (en) 1999-11-18 2003-03-20 Stefan Kochanek Permanent amniocyte cell line, its production and use for the production of gene transfer vectors
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
US6168941B1 (en) 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
DE10022258A1 (en) * 2000-05-08 2001-11-15 Bayer Ag Purification and/or concentration of protein inclusion bodies in solution, by passing the solution tangentially across semipermeable membrane formed from intersecting longitudinal and transverse fibers
JP2004508064A (en) 2000-09-15 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド Enhanced first generation adenovirus vaccine expressing codon-optimized HIV1-GAG, POL, NEF and modifications
US6365395B1 (en) * 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
EP1363997B1 (en) 2001-03-01 2011-01-19 Bayer Schering Pharma Aktiengesellschaft Concentration and lysis of adenovirus-infected cells in a single unit operation
AU2002327049B2 (en) 2001-10-01 2008-04-03 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
CA2478932A1 (en) 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
JP4495588B2 (en) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー Stable adenoviral vector and method for propagation thereof
US20050095705A1 (en) 2003-04-15 2005-05-05 Michael Kadan Method for production of oncolytic adenoviruses
AU2004249199B2 (en) * 2003-06-18 2008-07-24 Onyx Pharmaceuticals, Inc. Method for purifying virus
ES2329607T3 (en) 2004-02-23 2009-11-27 Crucell Holland B.V. VIRUS PURIFICATION METHODS
US20060078628A1 (en) * 2004-10-09 2006-04-13 Karl Koman Wound treating agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US20020182723A1 (en) * 1998-12-01 2002-12-05 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
WO2003097797A2 (en) * 2002-05-14 2003-11-27 Merck & Co., Inc. Methods of adenovirus purification

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRITTANTI L ET AL: "Optimised helper virus-free production of high-quality adeno-associated virus vectors.", THE JOURNAL OF GENE MEDICINE. 2001 JAN-FEB, vol. 3, no. 1, January 2001 (2001-01-01), pages 59 - 71, XP009033855, ISSN: 1099-498X *
GREEN ANTHONY P ET AL: "A new scalable method for the purification of recombinant adenovirus vectors", HUMAN GENE THERAPY, vol. 13, no. 16, 1 November 2002 (2002-11-01), pages 1921 - 1934, XP002293801, ISSN: 1043-0342 *
SULLIVAN N J ET AL: "Development of a preventive vaccine for Ebola virus infection in primates", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 408, no. 6812, 30 November 2000 (2000-11-30), pages 605 - 609, XP002242909, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
CN1922308A (en) 2007-02-28
ATE435906T1 (en) 2009-07-15
CN101343625A (en) 2009-01-14
JP2007522814A (en) 2007-08-16
WO2005080556A2 (en) 2005-09-01
AU2005214090B2 (en) 2008-09-11
DE602005015332D1 (en) 2009-08-20
ES2329607T3 (en) 2009-11-27
KR20070001163A (en) 2007-01-03
EP1780269A2 (en) 2007-05-02
NZ548495A (en) 2009-05-31
US20090017523A1 (en) 2009-01-15
US20070207461A1 (en) 2007-09-06
DK1780269T3 (en) 2009-10-12
EP1780269B1 (en) 2009-07-08
KR101211329B1 (en) 2012-12-12
US8124106B2 (en) 2012-02-28
AU2005214090A1 (en) 2005-09-01
EP1718738A2 (en) 2006-11-08
CA2555412C (en) 2013-06-25
WO2005080556A9 (en) 2006-10-26
CA2555412A1 (en) 2005-09-01
EP1780269A3 (en) 2007-07-18

Similar Documents

Publication Publication Date Title
WO2005080556A3 (en) Virus purification methods
WO2005081911A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5α
NO20052276L (en) Circulated DNA molecule with a conditional replication origin, method for their preparation and their use in gene therapy
BRPI0516572A (en) methods and compositions for improving the production of recombinant proteins
WO2008140621A3 (en) Transgenic oncolytic viruses and uses thereof
WO2010025302A3 (en) Apparatus for and method of processing biological samples
WO2005100395A3 (en) EXPRESSION SYSTEM FOR PREPARING IL-15/Fc FUSION PROTEINS AND ITS USE
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006012221A3 (en) Target cell-specific short interfering rna and methods of use thereof
WO2007095350A3 (en) Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
SI2330197T1 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
EP1555319A3 (en) Modified nucleic acid sequences and method to increasing mRNA levels and protein expression in cell systems
EP2184609A3 (en) Compositions and methods for treating lung cancer
ATE374828T1 (en) EXPRESSION VECTOR FOR ANTIBIOTIC-FREE EXPRESSION
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
WO2022056254A3 (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
DK2431470T3 (en) DNase expression in recombinant host cells
WO2002008263A3 (en) Modified virus having an altered tropism
CY1107431T1 (en) PARTICLES FOR GONAL TREATMENT
WO2010061187A3 (en) Method for the transformation of plant cell mitochondria
WO2007030674A3 (en) Use of nucleases to improve viability and enhance transgene expression in transfected cells
MX2021014952A (en) Binding molecule specific for cd73 and use of binding molecule.
ATE555196T1 (en) HEAT RESISTANT DUPLEX SPECIFIC NUCLEASE
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2009145606A8 (en) Method for the production of proteins or protein fragments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 548495

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005214090

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005214090

Country of ref document: AU

Date of ref document: 20050221

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005214090

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2555412

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005729676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006553596

Country of ref document: JP

Ref document number: 3061/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 10590427

Country of ref document: US

Ref document number: 2007207461

Country of ref document: US

Ref document number: 200580005682.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020067017560

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005729676

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067017560

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10590427

Country of ref document: US